Catherine Skari
-
Jul- 2020 -2 July
-
2 JulyNews
Thalassaemia Prior and Consequent to COVID-19 Pandemic: The Perspective of Thalassaemia International Federation (TIF)
Patients with haemoglobin disorders, particularly β-thalassaemia or sickle cell disease (SCD) or combined forms, on account of their underlying disease…
Read More » -
1 JulyNews
Advances in the Care & Cure of Thalassaemia: New Hopes & Challenges
TIF, in collaboration with Thalassemics India and Thalassemia Patients Advovacy Group – India, conducted on June 12, 2020 a Webinar…
Read More » -
Jun- 2020 -30 JuneNews
European Commission Approves Reblozyl for the Treatment of Transfusion-dependent β-Thalassaemia
Bristol Myers Squibb (BMS) & Acceleron Pharma announced today that the European Commission approved Reblozyl (luspatercept) for the treatment of Transfusion-Dependent…
Read More » -
29 June
-
25 June
-
22 JuneNews
COVID-19 & Haemoglobin Disorders: A TIF Webinar with Patients from America
On June 1st, TIF representatives, Dr Androulla Eleftheriou and Dr Michael Angastiniotis and Mr Loris Brunetta, Board Member, had a…
Read More » -
19 JuneWebinars
COVID-19 & Haemoglobin Disorders: The Impact of Coronavirus on Sickle Cell Disease Patients
An Expert Panel of Six Medical Professionals from various countries, such as India, the UK, Italy and Saudi Arabia, shared…
Read More » -
18 JuneWebinars
eThalED COURSE: Access to New Therapies – The Case of Reblozyl by Dr. Antonio Piga
The 1st webinar for Medical Specialists organised in the context of TIF’s eThalED online course is here. Dr Antonio Piga,…
Read More » -
16 JuneNews
TIF Thal e-Course: Testimonials from Online Learning Thalassaemia Patients
See what patients from various countries across the world who successfully took TIF‘s Thal e-Course, the ultimate self-paced, interactive, online Εducational…
Read More »
